BAJAJ BROKING
Cipla has received final US FDA approval for its New Drug Application (NDA) for Nilotinib Capsules 50, 150 & 200 mg, used for treating Philadelphia chromosome-positive chronic myeloid leukaemia (CML). The company plans to launch the drug in the US during FY 2025-26.
Cipla Limited has secured final approval from the United States Food and Drug Administration (US FDA) for its New Drug Application (NDA) for Nilotinib Capsules 50, 150 & 200 mg. This regulatory clearance strengthens Cipla’s presence in the oncology segment, particularly in the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), a severe blood cancer. The company plans to launch the product in the United States in the financial year 2025-26. This development further reinforces Cipla’s commitment to expanding its speciality medicine portfolio.
Also read: Burman Group Acquires Control of Religare Enterprises, Becomes Promoter
US FDA approval: Cipla’s NDA for Nilotinib Capsules has received final clearance on 19 February 2025.
Target disease: The drug is indicated for Philadelphia chromosome-positive chronic myeloid leukaemia (CML).
Dosage variants: Available in 50 mg, 150 mg, and 200 mg strengths.
Planned US launch: Cipla intends to introduce the drug in the US market during FY 2025-26.
Manufacturing compliance: Cipla’s Virgonagar facility in Bengaluru recently received a ‘Voluntary Action Indicated’ (VAI) status from the US FDA after a cGMP inspection.
Also read: Delta Corp Sells Deltatech Gaming to Head Digital Works for ₹491 Crore
Nilotinib is a key component in the treatment of CML, particularly in patients who are Philadelphia chromosome-positive. This approval marks an essential step for Cipla, as it continues to enhance its oncology offerings in the US. With the growing demand for targeted cancer therapies, the introduction of Nilotinib Capsules is expected to contribute significantly to Cipla’s revenues in the coming years.
Cipla’s consistent adherence to regulatory requirements is evident from its recent achievements. On 8 February 2025, Cipla announced that its Virgonagar manufacturing facility in Bengaluru received a ‘Voluntary Action Indicated’ (VAI) classification from the US FDA. This follows a routine cGMP inspection conducted in November 2024. The regulatory approval for Nilotinib Capsules further solidifies Cipla’s credibility in global markets.
Drug Name | Indication | US FDA Approval Date | Planned US Launch |
Nilotinib Capsules | Philadelphia chromosome-positive CML | 19 February 2025 | FY 2025-26 |
Respiratory drug X | Chronic obstructive pulmonary disease (COPD) | December 2024 | Q2 2025 |
Anti-infective drug Y | Bacterial infections | October 2024 | Q1 2025 |
The final approval for Nilotinib Capsules could positively influence Cipla share price, as investors anticipate strong revenue contributions from the US market. The company’s oncology pipeline, coupled with its compliance track record, positions it for potential stock market gains. Additionally, Cipla’s Virgonagar facility’s VAI classification reduces regulatory risks, further boosting investor confidence.
Cipla’s final US FDA approval for Nilotinib Capsules 50, 150 & 200 mg is a significant milestone in its oncology expansion. The planned launch in FY 2025-26 will strengthen its position in the US market. Given its growing pipeline and regulatory achievements, Cipla share price may see positive movement in the coming months.
Also read: ACE Ltd Secures ₹420 Crore Defence Contract for 1,121 RTFLTs
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading